You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNitric Oxide
Accession NumberDB00435  (APRD01142)
TypeSmall Molecule
GroupsApproved
DescriptionNitric oxide or Nitrogen monoxide is a chemical compound with chemical formula NO. This gas is an important signaling molecule in the body of mammals including humans and is an extremely important intermediate in the chemical industry. It is also a toxic air pollutant produced by automobile engines and power plants. Nitric oxide (NO) should not be confused with nitrous oxide (N2O), a general anaesthetic, or with nitrogen dioxide (NO2) which is another poisonous air pollutant. The nitric oxide molecule is a free radical, which is relevant to understanding its high reactivity. It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.
Structure
Thumb
Synonyms
(.)NO
(NO)(.)
[NO]
EDRF
endothelium-derived relaxing factor
Mononitrogen monoxide
Monoxido de nitrogeno
Monoxyde d'azote
Nitric oxide
nitrogen monooxide
Nitrogen monoxide
Nitrosyl
NO
NO(.)
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Stickstoff(ii)-oxid
Stickstoffmonoxid
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
InomaxInhalant400 ppmRespiratory (inhalation)Linde Healthcare Ab2001-08-01Not applicableEu
InomaxGas.98 mg/LRespiratory (inhalation)INO Therapeutics1999-12-23Not applicableUs
InomaxInhalant800 ppmRespiratory (inhalation)Linde Healthcare Ab2001-08-01Not applicableEu
InomaxGas.123 mg/LRespiratory (inhalation)INO Therapeutics1999-12-232015-12-29Us
InomaxInhalant800 ppmRespiratory (inhalation)Linde Healthcare Ab2001-08-01Not applicableEu
InomaxGas800 ppmRespiratory (inhalation)INO Therapeutics2005-11-23Not applicableCanada
InomaxInhalant400 ppmRespiratory (inhalation)Linde Healthcare Ab2001-08-01Not applicableEu
InomaxGas100 ppmRespiratory (inhalation)INO Therapeutics2005-11-232015-07-31Canada
KinoxGas800 ppmRespiratory (inhalation)Air Liquide Healthcare America Corporation2016-05-03Not applicableCanada
KinoxGas100 ppmRespiratory (inhalation)Air Liquide Healthcare America Corporation2016-05-03Not applicableCanada
NoxiventGas100 ppmRespiratory (inhalation)Praxair Canada Inc2016-03-10Not applicableCanada
NoxiventGas800 ppmRespiratory (inhalation)Praxair Canada Inc2016-03-10Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Nitric Oxide Nitrogen MixAirgas Specialty Gases
SaltsNot Available
Categories
UNII31C4KY9ESH
CAS number10102-43-9
WeightAverage: 30.0061
Monoisotopic: 29.997988627
Chemical FormulaNO
InChI KeyMWUXSHHQAYIFBG-UHFFFAOYSA-N
InChI
InChI=1S/NO/c1-2
IUPAC Name
nitroso
SMILES
[N]=O
Pharmacology
IndicationFor the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure
Structured Indications
PharmacodynamicsPersistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale. In neonates with PPHN, Nitric oxide improves oxygenation (as indicated by significant increases in PaO2). Nitric oxide appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better entilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.
Mechanism of actionNitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide produces pulmonary vasodilation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Guanylate cyclase soluble subunit alpha-2Proteinyes
inducer
HumanP33402 details
Related Articles
AbsorptionNitric oxide is absorbed systemically after inhalation.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

via pulmonary capillary bed

Route of eliminationNitrate has been identified as the predominant nitric oxide metabolite excreted in the urine, accounting for >70% of the nitric oxide dose inhaled.
Half life2–6 seconds
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ornithine Aminotransferase Deficiency (OAT Deficiency)DiseaseSMP00363
Prolidase Deficiency (PD)DiseaseSMP00207
Arginine and Proline MetabolismMetabolicSMP00020
Prolinemia Type IIDiseaseSMP00208
Hyperprolinemia Type IDiseaseSMP00361
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)DiseaseSMP00188
Hyperprolinemia Type IIDiseaseSMP00360
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)DiseaseSMP00362
Creatine deficiency, guanidinoacetate methyltransferase deficiencyDiseaseSMP00504
Hyperornithinemia with gyrate atrophy (HOGA)DiseaseSMP00505
Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome]DiseaseSMP00506
L-arginine:glycine amidinotransferase deficiencyDiseaseSMP00507
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Nitric Oxide can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nitric Oxide.Approved
AcetaminophenThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitric Oxide.Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Nitric Oxide.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Nitric Oxide.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nitric Oxide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitric Oxide.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nitric Oxide.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nitric Oxide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitric Oxide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Amyl Nitrite.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nitric Oxide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nitric Oxide.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Nitric Oxide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitric Oxide.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitric Oxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nitric Oxide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nitric Oxide.Approved
AzithromycinThe metabolism of Nitric Oxide can be decreased when combined with Azithromycin.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Nitric Oxide.Experimental
BarbitalBarbital may increase the hypotensive activities of Nitric Oxide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nitric Oxide.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nitric Oxide.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nitric Oxide.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Benzocaine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitric Oxide.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nitric Oxide.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nitric Oxide.Approved
BortezomibThe metabolism of Nitric Oxide can be decreased when combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Nitric Oxide.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nitric Oxide.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitric Oxide.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nitric Oxide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitric Oxide.Approved, Investigational
ButalbitalThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Butalbital.Approved, Illicit
CaffeineThe metabolism of Nitric Oxide can be decreased when combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Nitric Oxide.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nitric Oxide.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nitric Oxide.Approved
CarbamazepineThe metabolism of Nitric Oxide can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitric Oxide.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nitric Oxide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nitric Oxide.Approved, Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Celecoxib.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nitric Oxide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitric Oxide.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nitric Oxide.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nitric Oxide.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitric Oxide.Approved
CitalopramThe metabolism of Nitric Oxide can be decreased when combined with Citalopram.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Nitric Oxide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nitric Oxide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitric Oxide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nitric Oxide.Approved
ClotrimazoleThe metabolism of Nitric Oxide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitric Oxide.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nitric Oxide.Approved, Investigational
Cyproterone acetateThe serum concentration of Nitric Oxide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Nitric Oxide.Approved
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Nitric Oxide.Approved, Investigational
DeferasiroxThe serum concentration of Nitric Oxide can be increased when it is combined with Deferasirox.Approved, Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitric Oxide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitric Oxide.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nitric Oxide.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nitric Oxide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Nitric Oxide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nitric Oxide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nitric Oxide.Approved
DuloxetineNitric Oxide may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nitric Oxide.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitric Oxide.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nitric Oxide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitric Oxide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nitric Oxide.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Nitric Oxide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nitric Oxide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitric Oxide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nitric Oxide.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nitric Oxide.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nitric Oxide.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitric Oxide.Approved
FlutamideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Flutamide.Approved
FluvoxamineThe metabolism of Nitric Oxide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nitric Oxide.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nitric Oxide.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nitric Oxide.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nitric Oxide.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Nitric Oxide.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nitric Oxide.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nitric Oxide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nitric Oxide.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Nitric Oxide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitric Oxide.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitric Oxide.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nitric Oxide.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Nitric Oxide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nitric Oxide.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nitric Oxide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nitric Oxide.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isometheptene.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Nitric Oxide.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nitric Oxide.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Nitric Oxide.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Nitric Oxide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nitric Oxide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nitric Oxide.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitric Oxide.Approved
LevodopaNitric Oxide may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nitric Oxide.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nitric Oxide.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Nitric Oxide.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nitric Oxide.Approved
MafenideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Mafenide.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nitric Oxide.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nitric Oxide.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nitric Oxide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nitric Oxide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitric Oxide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nitric Oxide.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nitric Oxide.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nitric Oxide.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nitric Oxide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitric Oxide.Approved, Investigational
MexiletineThe metabolism of Nitric Oxide can be decreased when combined with Mexiletine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nitric Oxide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nitric Oxide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nitric Oxide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Nitric Oxide.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitric Oxide.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Nitric Oxide.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Nitric Oxide.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Nitric Oxide.Approved, Investigational
NevirapineThe metabolism of Nitric Oxide can be decreased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nitric Oxide.Approved
NicorandilNicorandil may increase the hypotensive activities of Nitric Oxide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nitric Oxide.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Nitric Oxide.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nitric Oxide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nitric Oxide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide.Approved
NitrofurantoinThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nitrofurantoin.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nitroprusside.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitric Oxide.Approved, Investigational
OsimertinibThe serum concentration of Nitric Oxide can be decreased when it is combined with Osimertinib.Approved
OxprenololThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nitric Oxide.Approved
Peginterferon alfa-2bThe serum concentration of Nitric Oxide can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Nitric Oxide.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Nitric Oxide.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nitric Oxide.Approved
PhenazopyridineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenazopyridine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenelzine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenytoin.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nitric Oxide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nitric Oxide.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Prilocaine.Approved
PrimaquineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Primaquine.Approved
PrimidoneThe metabolism of Nitric Oxide can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nitric Oxide.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitric Oxide.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nitric Oxide.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nitric Oxide.Approved
RasagilineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitric Oxide.Approved
RifampicinThe metabolism of Nitric Oxide can be increased when combined with Rifampicin.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Nitric Oxide.Approved
RisperidoneNitric Oxide may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe metabolism of Nitric Oxide can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sacubitril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Nitric Oxide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sevoflurane.Approved, Vet Approved
SimeprevirThe metabolism of Nitric Oxide can be decreased when combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitric Oxide.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nitric Oxide.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sufentanil.Approved, Investigational
SulfadiazineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sulfamethoxazole.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nitric Oxide.Approved, Investigational
TenofovirThe metabolism of Nitric Oxide can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Nitric Oxide.Approved
TeriflunomideThe serum concentration of Nitric Oxide can be decreased when it is combined with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Nitric Oxide can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Nitric Oxide.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nitric Oxide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Thioridazine.Approved
TiclopidineThe metabolism of Nitric Oxide can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nitric Oxide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nitric Oxide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nitric Oxide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nitric Oxide.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nitric Oxide.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitric Oxide.Approved, Investigational
VemurafenibThe serum concentration of Nitric Oxide can be increased when it is combined with Vemurafenib.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nitric Oxide.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Zopiclone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Stephen M. Campbell, Chen-Youn Sue, “Nitric oxide for vapor phase elimination of styrene and acrylonitrile popcorn polymer in bulk SAN production.” U.S. Patent US5272231, issued November, 1968.

US5272231
General References
  1. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 Jan;87(1):315-424. [PubMed:17237348 ]
External Links
ATC CodesR07AX01
AHFS Codes
  • 24:12.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9785
Caco-2 permeable+0.6149
P-glycoprotein substrateNon-substrate0.9034
P-glycoprotein inhibitor INon-inhibitor0.957
P-glycoprotein inhibitor IINon-inhibitor0.9892
Renal organic cation transporterNon-inhibitor0.8973
CYP450 2C9 substrateNon-substrate0.8884
CYP450 2D6 substrateNon-substrate0.888
CYP450 3A4 substrateNon-substrate0.7535
CYP450 1A2 substrateNon-inhibitor0.7402
CYP450 2C9 inhibitorNon-inhibitor0.9383
CYP450 2D6 inhibitorNon-inhibitor0.896
CYP450 2C19 inhibitorNon-inhibitor0.8796
CYP450 3A4 inhibitorNon-inhibitor0.9754
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8945
Ames testAMES toxic0.5342
CarcinogenicityCarcinogens 0.8336
BiodegradationReady biodegradable0.9371
Rat acute toxicity2.5108 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8524
hERG inhibition (predictor II)Non-inhibitor0.9756
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ino therapeutics inc
Packagers
Dosage forms
FormRouteStrength
GasRespiratory (inhalation).123 mg/L
GasRespiratory (inhalation).98 mg/L
GasRespiratory (inhalation)100 ppm
GasRespiratory (inhalation)800 ppm
InhalantRespiratory (inhalation)400 ppm
InhalantRespiratory (inhalation)800 ppm
GasRespiratory (inhalation)
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2186892 No2007-11-272015-04-03Canada
US5485827 No1993-01-232013-01-23Us
US5732693 Yes1997-06-132017-06-13Us
US5752504 Yes1997-06-132017-06-13Us
US6125846 Yes1997-11-162017-11-16Us
US8282966 Yes2009-12-302029-12-30Us
US8291904 Yes2011-07-062031-07-06Us
US8293284 Yes2009-12-302029-12-30Us
US8431163 Yes2009-12-302029-12-30Us
US8573209 Yes2011-07-062031-07-06Us
US8573210 Yes2011-07-062031-07-06Us
US8776794 Yes2011-07-062031-07-06Us
US8776795 Yes2011-07-062031-07-06Us
US8795741 Yes2009-12-302029-12-30Us
US8846112 Yes2009-12-302029-12-30Us
US9265911 Yes2011-07-062031-07-06Us
US9279794 Yes2014-08-192034-08-19Us
US9295802 Yes2011-07-062031-07-06Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point-163.6 °CPhysProp
boiling point-151.7 °CPhysProp
water solubility9.49E+004 mg/LNot Available
logP0Not Available
Predicted Properties
PropertyValueSource
logP-0.35ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity2.89 m3·mol-1ChemAxon
Polarizability1.69 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (6.86 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-001i-9000000000-8a2dd9da1fc114d013b3View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-001i-9000000000-8a2dd9da1fc114d013b3View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-001i-9000000000-8a2dd9da1fc114d013b3View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-004i-9000000000-e998110984a05853a05dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-004i-9000000000-e998110984a05853a05dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-004i-9000000000-e998110984a05853a05dView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as homogeneous other non-metal compounds. These are inorganic non-metallic compounds in which the largest atom belongs to the class of 'other nonmetals'.
KingdomInorganic compounds
Super ClassHomogeneous non-metal compounds
ClassHomogeneous other non-metal compounds
Sub ClassNot Available
Direct ParentHomogeneous other non-metal compounds
Alternative Parents
Substituents
  • Homogeneous other non metal
  • Inorganic oxide
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Heme binding
Specific Function:
Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.
Gene Name:
GUCY1A2
Uniprot ID:
P33402
Molecular Weight:
81749.185 Da
References
  1. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109-42. [PubMed:1852778 ]
  2. Mancuso C, Navarra P, Preziosi P: Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem. 2010 May;113(3):563-75. doi: 10.1111/j.1471-4159.2010.06606.x. Epub 2010 Jan 20. [PubMed:20089135 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Electron carrier activity
Specific Function:
Not Available
Gene Name:
ALDH2
Uniprot ID:
P05091
Molecular Weight:
56380.93 Da
References
  1. Moon KH, Kim BJ, Song BJ: Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation. FEBS Lett. 2005 Nov 7;579(27):6115-20. Epub 2005 Oct 11. [PubMed:16242127 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Nakano R, Sato H, Watanabe A, Ito O, Shimizu T: Conserved Glu318 at the cytochrome P450 1A2 distal site is crucial in the nitric oxide complex stability. J Biol Chem. 1996 Apr 12;271(15):8570-4. [PubMed:8621484 ]
  2. Mulero-Navarro S, Santiago-Josefat B, Pozo-Guisado E, Merino JM, Fernandez-Salguero PM: Down-regulation of CYP1A2 induction during the maturation of mouse cerebellar granule cells in culture: role of nitric oxide accumulation. Eur J Neurosci. 2003 Oct;18(8):2265-72. [PubMed:14622187 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Aitken AE, Lee CM, Morgan ET: Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med. 2008 Mar 15;44(6):1161-8. doi: 10.1016/j.freeradbiomed.2007.12.010. Epub 2007 Dec 23. [PubMed:18206661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Watabe M, Isogai Y, Numazawa S, Yoshida T: Role of c-Myc in nitric oxide-mediated suppression of cytochrome P450 3A4. Life Sci. 2003 Nov 21;74(1):99-108. [PubMed:14575816 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54